Commercial maturation of MedicQuant

MedicQuant is an in vitro diagnostic company where we have invented a deep-tech platform technology that will revolutionize small molecule diagnostics. Our first product, DoaQuant, focuses on improving stroke management. In the event of stroke rapid treatment is vital for survival and every minute matters.

It is crucial to determine the level of anticoagulant (AC) drugs in these patients, as this determines which lifesaving treatment can be given. Current diagnostic solutions take more than 40 minutes thus risking patients’ lives.

DoaQuant can rapidly provide clinicians with the answer they need to determine the correct life-saving management in stroke, thus greatly reducing delay in treatment, mortality, and disability. Dr.

Line Debois is CEO and co-founder of MedicQuant and has, through her academic career, researched biosensors concluding in the co-invention of the technology behind MedicQuant.

She has taken the position of CEO in MedicQuant since incorporation, with the vision to lead the company to success and make a difference in the healthcare system.

The overall goal with the activities performed during the Women TechEU program is commercial maturation of MedicQuant and preparing for VC fundraising. This will be achieved through specific tasks and by further developing CEO Line’s commercial and leadership skills.

The specific activities to achieve this is making a market access strategy (through reimbursement analysis, regulatory strategy, pricing strategy and willingness to buy), preparation of documentation portfolio for investment and further developing commercial skills through the mentoring program that are needed for VC fundraise and manage a company in growth.

This program will directly help overcoming the most crucial commercial challenges that both MedicQuant and Line as CEO are currently facing, thereby enabling MedicQuant to become a female lead success, empowering women in deep-tech and fostering further diversity in the life-science sector.